Cerebral organoids reveal early cortical maldevelopment in schizophrenia-computational anatomy and genomics, role of FGFR1.
- Authors
- Stachowiak, E K; Benson, C A; Narla, S T; Dimitri, A; Chuye, L E Bayona; Dhiman, S; Harikrishnan, K; Elahi, S; Freedman, D; Brennand, K J; Sarder, P; Stachowiak, M K
- Year
- 2017
- Journal
- Translational psychiatry
- PMID
- 30446636
- DOI
- 10.1038/s41398-017-0054-x
- PMCID
- PMC5802550
Studies of induced pluripotent stem cells (iPSCs) from schizophrenia patients and control individuals revealed that the disorder is programmed at the preneuronal stage, involves a common dysregulated mRNA transcriptome, and identified Integrative Nuclear FGFR1 Signaling a common dysregulated mechanism. We used human embryonic stem cell (hESC) and iPSC-derived cerebral organoids from four controls and three schizophrenia patients to model the first trimester of in utero brain development. The schizophrenia organoids revealed an abnormal scattering of proliferating Ki67+ neural progenitor cells (NPCs) from the ventricular zone (VZ), throughout the intermediate (IZ) and cortical (CZ) zones. TBR1 pioneer neurons and reelin, which guides cortico-petal migration, were restricted from the schizophrenia cortex. The maturing neurons were abundantly developed in the subcortical regions, but were depleted from the schizophrenia cortex. The decreased intracortical connectivity was denoted by changes in the orientation and morphology of calretinin interneurons. In schizophrenia organoids, nuclear (n)FGFR1 was abundantly expressed by developing subcortical cells, but was depleted from the neuronal committed cells (NCCs) of the CZ. Transfection of dominant negative and constitutively active nFGFR1 caused widespread disruption of the neuro-ontogenic gene networks in hESC-derived NPCs and NCCs. The fgfr1 gene was the most prominent FGFR gene expressed in NPCs and NCCs, and blocking with PD173074 reproduced both the loss of nFGFR1 and cortical neuronal maturation in hESC cerebral organoids. We report for the first time, progression of the cortical malformation in schizophrenia and link it to altered FGFR1 signaling. Targeting INFS may offer a preventive treatment of schizophrenia.
Representative hESC (H9) cerebral organoids at (a) 8 and (b) 18 days of development(a1, b1) tile scanning of DAPI; yellow arrows point to cortical rosettes, enlarged in a2 and b2; at day 18, zones are outlined—ventricular zone (VZ), intermediate zone (IZ), and cortical zone (CZ). Immunostaining: (A4, B5) Ki67+ proliferating cells; (a3, b3, b4), doublecortin (DCX+) neuroblasts, βIII-tubulin+ immature neurons
LLM interpretation
This figure presents immunostaining and DAPI microscopy images of hESC (H9) cerebral organoids at day 8 (top row) and day 18 (bottom row) of development. Low-magnification tile scans (a1, b1) and enlarged views (a2, b2) highlight the formation of cortical rosettes and the emergence of distinct ventricular (VZ), intermediate (IZ), and cortical (CZ) zones by day 18. Additional panels show the localization of Ki67+ proliferating cells, DCX+ neuroblasts, and $\beta$III-tubulin+ immature neurons.
Disorganized migration of proliferating cells and depletion of cortical neurons in schizophrenia iPSC cerebral organoidsOrganoids were coimmunostained for Ki67 (red) and Pan-Neu (green). Nuclei were stained with DAPI (blue). a 2-week organoids—images show representative sections of organoids, control (iPSC line BJ1) and schizophrenia (iPSC line 1835). In schizophrenia organoids, note the dispersion of proliferating (Ki67+) cells outside the VZ into IZ and CZ, fewer mature Pan-Neu+ neurons in CZ, and the appearance of Pan Neu+ neurons in the IZ. b 5-week iPSC organoids: control (line 2937) and schizophrenia (line 2038)—representative images of control and schizophrenia organoids. In schizophrenia organoids, note dispersion of Ki67+ cells into CZ, reduced density of Pan Neu+ neurites in basal CZ and the presence of Pan Neu+ cells with neurites in the IZ. 3D rotational confocal images of control (line 3651) and schizophrenia (line 1835) organoids are shown in Video 1a and b. Pan-Neu immunofluorescence intensity was measured in multiple randomly selected ROI (1 × 102 μm2 in basal cortex (*) and in IZ (**)). c 5-week organoids—Pan-Neu immunofluorescence intensity was measured in several ROIs (# shown on y-axis) of multiple organoids from three control and three schizophrenia patients. Note, significantly reduced Pan-Neu fluorescence intensity in basal cortex of the schizophrenia organoids and the lack of significant changes in the IZ. d Distribution of Pan-Neu intensity numbers in analyzed ROIs. Note the significant separation of the basal cortex plots in control and schizophrenia organoids and the lack of separation of the IZ plots
LLM interpretation
This figure consists of immunofluorescence microscopy images (a, b), a bar chart (c), and density plots (d) comparing control and schizophrenia iPSC cerebral organoids. The microscopy images show Ki67 (red), Pan-Neu (green), and DAPI (blue) staining, highlighting a dispersion of proliferating cells and reduced Pan-Neu+ neurons in the cortical zone (CZ) of schizophrenia organoids. The bar chart indicates a statistically significant reduction in Pan-Neu fluorescence intensity in the basal cortex of schizophrenia organoids compared to controls (*), with no significant difference (NS) in the intermediate zone (IZ). The density plots further illustrate a clear separation in Pan-Neu intensity distributions for the basal cortex between the two groups, while the IZ distributions overlap.
Quantification of disorganized migration of proliferating NPCs in schizophrenia compared to control cerebral organoids a Exemplary images showing Ki67+ (red) proliferating NPCs in the center of the rosette of a control organoid (line 2937) and their dispersion in a schizophrenia organoid (line 2038) (nuclei were stained with DAPI). b Increased density of proliferating cells in schizophrenia organoids. ROIs were outlined on organoid images from three control and three schizophrenia patients, as shown in (c1). Bar graph shows significantly higher average numbers of the KI67+ proliferating cells in schizophrenia ROIs than in control ROIs (17 control and 20 schizophrenia ROIs quantified). c Global Minimum Spanning Tree (MST) analysis of Ki67+ NPC dispersion within ROIs (c1—examples) was carried out using 17 control and 20 schizophrenia ROIs from three control cases and three schizophrenia patients (total of 649 and 1070 cells analyzed, respectively). The shortest connecting edges between cells were identified in pixels (c2) using MST calculating program and were grouped into bins (c3). Bin 1 contains edges of 0–5 pixels, bin 2 of 5–10 pixels, etc. Frequency indicates average numbers of cells per bin in all ROIs measured. Schizophrenia organoids displayed a shift towards longer MST distances. Two-Way ANOVA showed a significant interaction between organoid phenotype (control vs. disease) and the MST distances
LLM interpretation
This figure compares proliferating NPCs in control and schizophrenia cerebral organoids using microscopy and quantitative analysis. Panel (a) and (c1) show Ki67+ (red) cells, with a bar graph in (b) indicating a significantly higher average cell density per ROI in schizophrenia organoids ($p < 0.01$). Panels (c2) and (c3) utilize Minimum Spanning Tree (MST) analysis to show that schizophrenia organoids exhibit a shift toward longer distances between cells, with a Two-Way ANOVA confirming a significant interaction between phenotype and MST distance ($p < 0.0001$).
(a) Decreased nuclear TBR1 (red) expression in the upper cortical zone of 5-week schizophrenia organoidsNuclei were stained with DAPI. Images show representative sections of control (iPSC line BJ1) and schizophrenia (iPSC line 2038) organoids. Total number of DAPI-stained nuclei and the number of nuclei expressing TBR1 were counted in multiple randomly selected ROI (5 × 103 μm2, ∼50 cells/ ROI) within the upper cortical layers (*6 cells deep) of three control individuals and three patients. Percent of (TBR1 + DAPI)/DAPI-stained nuclei was determined for each ROI. Graph shows distribution of the % of TBR1 expressing cells in the individual ROIs (26 control and 33 schizophrenia ROIs). The difference between control and schizophrenia mean values was significant (t-test). Individual value plots are shown in Supplementary Fig. 5b. b Decreased reelin expression in schizophrenia organoid cortex. Images show control (BJ1) and schizophrenia (1835) organoids. Note the lack of reelin staining in 2-week organoids. In 5-week organoids, reelin immunofluorescence intensity was determined in randomly selected ROIs (3 × 103 μm2) in the upper CZ (*) and in the IZ (**) regions of three control individuals and three patients using Zen 2.0 Blue Imaging software (22 control and 17 schizophrenia upper CZ ROIs and the same number of IZ ROIs). ANOVA of four groups followed by Tukey posthoc test showed a significant decrease in the reelin expression in the schizophrenia upper CZ and a lack of significant differences between control and schizophrenia in the IZ. Individual value plots are shown in Supplementary Fig. 5. c Morphology and orientation of cortical calretinin interneurons. c1—images of control and schizophrenia organoids. A total of 770 control and 547 schizophrenia calretinin interneurons were measured in 20 and 16 ROIs, respectively, in the organoids from three control and three schizophrenia patients. The average cell density (d = number of cells/ROI) was not significantly different between control and schizophrenia (Supplementary Fig. 3a, b). c2—graph shows cell distribution (cumulative frequency) relative to their total length, including the cell body and neurites. An average cell body had a length of ∼50 pixels, 18 μm. A two-sample Kolmogorov–Smirnov test of cumulative density function (CDF shown in the inset) of control and schizophrenia groups found no significant difference between the length of control and schizophrenia interneurons. c3—angles between the long axis of each cell and the cortical surface organoids were computed as described in the Supplementary Methods. Graph shows distribution of cells (cumulative frequency) in bins corresponding to the deviation angles from the cortical surface. A two-sample Kolmogorov–Smirnov CDF test (CDFs shown in the inset) of control and schizophrenia groups yielded a highly significant difference (p-value of <13.9 × 10−7) between the orientation of control and schizophrenia interneurons, relative to the cortical surface
LLM interpretation
This figure consists of immunofluorescence images and quantitative graphs comparing control and schizophrenia iPSC-derived organoids. Panel (a) shows a decrease in nuclear TBR1 expression in schizophrenia organoids, supported by a frequency distribution plot ($P=0.001$). Panel (b) uses a bar chart to show significantly decreased reelin fluorescence intensity in the upper cortical zone (CZ) of schizophrenia organoids compared to controls, while the intermediate zone (IZ) shows no significant difference. Panel (c) includes microscopy images of calretinin interneurons and histograms showing no significant difference in cell length (c2), but a highly significant difference in cell orientation relative to the cortical surface (c3, $p < 13.9 \times 10^{-7}$).
High expression of nuclear (n)FGFR1 in subcortical cells and the loss of nFGFR1 in cortical cells of schizophrenia organoids. a 2-week organoids: control (iPSC line BJ1) and schizophrenia (iPSC line 1835). Schizophrenia organoids have high FGFR1 expressing cells in VZ and dispersed in IZ. Few nFGFR1+ cells are present in CZ of the schizophrenia organoids. Images of whole sections are shown in Supplementary Fig. 4, a4 and a5. b 5-week organoids—control (BJ1) organoids express nFGFR1 in CZ and IZ (inset shows negative control—omitted primary FGFR1 antibody), and schizophrenia (1835) organoids show depletion of FGFR1 immunostaining in CZ. Arrow points to nuclei with FGFR1 speckles. 3D rotational confocal images of control (line 3651) and schizophrenia (line 1835) organoids are shown in Video 2a and b. c Quantification of the % of DAPI-stained nuclei that were immunopositive for nFGFR1 in multiple randomly selected ROI (3 × 103 μm2, ∼40 cells/ ROI) in the upper CZ. The % of nFGFR1+ DAPI-stained nuclei was determined for multiple ROIs from the three control individuals and three patients. The difference between control and schizophrenia mean values was significant (t-test). Plots show distribution of the % of nFGFR1 positive nuclei in individual control (18 ROIs) and schizophrenia (12 ROIs). The individual value plots are shown in Supplementary Fig. 5d
LLM interpretation
This figure consists of immunofluorescence microscopy images (a, b) and quantitative data (c) comparing nFGFR1 expression in control and schizophrenia organoids. The microscopy images show a depletion of nFGFR1 immunostaining in the cortical zone (CZ) of schizophrenia organoids compared to controls at 2 and 5 weeks. The quantification in panel c includes a bar chart and a density distribution plot showing a significantly lower percentage of nFGFR1+ nuclei in schizophrenia organoids compared to controls (p < 0.001).
(a) Histogram of pairwise mRNA correlationsCorrelation was performed using three controls and three patients and triplicate cell samples. NPCs were transfected with control DNA or FGFR1(SP-/NLS)(TK-) and 24 h later were stimulated for 48 h with neuronal differentiation inducing media with cAMP/BDNF/GDNF (NCCs). Genes (861), which were affected by dominant negative nuclear FGFR1(SP-/NLS)(TK-) were analyzed. Genes that showed the highest positive (+0.9 to +1.0) correlations (changing in the same direction) are represented by the gray bar. Genes that showed the highest negative (−0.9 to −1.0) correlations (changing in the opposite directions) are shown as a black bar. b, c Among the FGFR1(SP-/NLS)(TK-) regulated genes, top 200 of the positively correlated genes (b) and top 200, which were negatively correlated genes (c) were selected for the circular network analysis. Gray lines link pairs of genes whose correlation is greater than 0.9. In the control β-galactosidase set, three separate networks were formed. In the FGFR1(SP-/NLS)(TK-) transfected cells, two weakly correlated networks and few individual correlated genes are observed. GO categories overrepresented by 200 top connected genes are listed
LLM interpretation
This figure consists of two histograms (a) and two sets of circular network diagrams (b, c). The histograms show the frequency of pairwise mRNA correlations for NCCs transfected with $\beta$-gal (control) versus FGFR1(SP-/NLS)(TK-), with both groups exhibiting peaks at the highest positive (gray) and negative (black) correlation values. The network diagrams visualize the top 200 positively (b) and negatively (c) correlated genes, showing a transition from dense, highly connected networks in the control group to sparse, weakly connected networks in the FGFR1-transfected group, accompanied by lists of overrepresented GO categories.
Treatment with PD173074 (days 8 and 18) affects cortical development in hESC H9 organoids a Double staining for DAPI and doublecortin (DBX, neuroblasts). b PD173074 reduces expression of calretinin in hESC organoids. c BrdU pulse-chase experiment. c—control hESC organoids, d—PD173074 treated (days 8 and 18) organoids. PD173074 inhibits cortical migration and neuronal differentiation of newborn cells in hESC organoids. Sections were coimmunostained for BrdU (red), Pan-Neu (green), and DAPI (blue). Merged and individual stains are shown. Inhibition of FGFR1 with PD173074 inhibits migration and formation of new BrdU+ cortical neurons in the CZ
LLM interpretation
This figure consists of immunofluorescence microscopy images comparing control and PD173074-treated hESC H9 organoids. Panel (a) shows DAPI (blue) and doublecortin (DBX, red) staining, while panel (b) shows calretinin (red) expression, both of which appear reduced in the treated group. Panel (c) displays a BrdU pulse-chase experiment with co-staining for Pan-Neu (green), BrdU (red), and DAPI (blue), showing a higher concentration of BrdU+ cells and reduced Pan-Neu expression in the PD173074-treated organoids compared to the control.
a Distribution of FGFR1 in zones of hESC H9 organoids (fluorescent microscope images). b Reduction of nFGFR1 in CZ after PD173074 treatment (days 8–18)—confocal analysis of FGFR1 and DAPI co-staining; (b1) control and (b2) PD173074-treated cerebral organoids. (b3) control and (b4) PD173074, areas zoomed 63×. c Percentage of nFGFR1 expressing cells in CZ was reduced by PD173074—nFGFR1+ nuclei were counted in sets of 100 DAPI-stained nuclei. d Left—reference stratification of developing telencephalon and zones of cerebral organoids—ventricular (VZ), intermediate (IZ), cortical (CZ), marginal (MZ); middle and right—summary of results—in schizophrenia organoids, we found the following changes: (i) increased proliferation of Ki67 NPCs and migration outside the VZ into the IZ and CZ, (ii) diminished deposition of reelin in the developing cortex (known to guide cortico-petal migration), (iii) reduced cortical accumulation of pioneer TBR1 neurons and reduced formation of cortical neurons, (iv) stunted cortical neuronal development accompanied by a robust formation of the subcortical neurons, and (v) fewer calretinin interneurons forming horizontal processes (known to connect cortical columns). The premature development of NPCs into subcortical neurons may reflect excessive nFGFR1 (+)* signaling in differentiating schizophrenia NPCs (as found in earlier genomic studies55). On the other hand, stunted cortical development likely reflects the loss of cortical nFGFR1 signaling. Modeling this loss in hESC organoids, by blocking FGFR1 signaling and depleting nFGFR1 with PD173074, replicates the impaired cortical development observed in schizophrenia iPSC organoids. The loss of cortical nnFGFR1 may underlie the stunted cortical development in schizophrenia
LLM interpretation
This figure consists of fluorescent microscopy images, a bar chart, and a schematic diagram. Panels (a) and (b) show FGFR1 (red) and DAPI (blue) staining in hESC H9 organoids, with a visible reduction of nuclear FGFR1 in the cortical zone (CZ) following PD173074 treatment. The bar chart in (c) quantifies this reduction, showing a decrease in nFGFR1-expressing cells from 52% in the control to 15% in the PD173074 group. Panel (d) provides a schematic comparing brain developmental strata (VZ, IZ, CZ) between control and schizophrenia organoids, illustrating altered NPC proliferation, reduced Reelin and TBR1 expression, and stunted cortical neuronal development.
| Name | Type |
|---|---|
| 1835 local | cohort |
| 2038 local | cohort |
| 2nd messenger signaling local | phenotype |
| Abnormal connections local | phenotype |
| angiogenesis | phenotype |
| antibodies | drug |
| apoptosis | phenotype |
| Apoptosis, neuron apoptosis local | phenotype |
| Ascl1 | gene |
| ascorbic acid | drug |
| autism | phenotype |
| autism patients | cohort |
| autism spectrum disorders | phenotype |
| axonal guidance | phenotype |
| Axon development local | phenotype |
| Basal Cortex local | anatomy |
| basal CZ local | anatomy |
| Bdnf | gene |
| BJ1 local | cohort |
| body axes development local | phenotype |
| bone development local | phenotype |
| brain development | phenotype |
| Brain parts development local | phenotype |
| BrdU | drug |
| BrdU+ cortical neurons local | phenotype |
| CALB2 | gene |
| calcium | drug |
| calcium signaling | phenotype |
| calretinin | drug |
| calretinin interneurons local | phenotype |
| calretinin+ interneurons local | phenotype |
| cAMP | drug |
| Cannon and Keller water-shed model of schizophrenia local | cohort |
| Cardiovascular development local | phenotype |
| cell adhesion | phenotype |
| Cell–cell signaling local | phenotype |
| cell cycle | phenotype |
| cell migration | phenotype |
| Cell, neuronal differentiation local | phenotype |
| Cell paucity local | phenotype |
| cell proliferation | phenotype |
| Cell proliferation, mitotic cycle local | phenotype |
| cellular organization local | phenotype |
| Cellular response to TGFβ local | phenotype |
| cerebral organoid local | anatomy |
| Cerebral organoid local | anatomy |
| Cerebral organoid local | drug |
| cerebral organoid model local | drug |
| cerebral organoids local | anatomy |
| cerebral organoids local | cohort |
| Childhood schizophrenia local | phenotype |
| cognitive symptoms | phenotype |
| constitutively_active_nFGFR1_SP_NLS local | variant |
| control | cohort |
| Control_2937 local | cohort |
| Control_3440 local | cohort |
| Control_3651 local | cohort |
| Control_BJ#1 local | cohort |
| control DNA local | drug |
| control hESC organoids local | cohort |
| control iPSC line organoids local | cohort |
| Control iPSC lines local | cohort |
| control iPSC organoids local | cohort |
| Control iPSC organoids local | cohort |
| control organoids | cohort |
| controls | cohort |
| control subjects | cohort |
| control β-galactosidase transfected NCCs local | cohort |
| cortex | anatomy |
| Cortical connections local | anatomy |
| Cortical fields local | anatomy |
| cortical layer II local | anatomy |
| cortical layer III local | anatomy |
| cortical layers | anatomy |
| cortical layer V1 local | anatomy |
| cortical malformations | phenotype |
| cortical migration local | phenotype |
| cortical neuronal development local | phenotype |
| cortical neurons | anatomy |
| cortical plate | anatomy |
| cortical rosettes local | anatomy |
| cortical rosettes local | phenotype |
| Cortical zone (CZ) local | anatomy |
| Cortical Zone (CZ) local | anatomy |
| CREBBP | gene |
| CXCR4 | gene |
| Cz | anatomy |
| DAPI | drug |
| DAPI staining local | drug |
| DCX | gene |
| decreased activity local | phenotype |
| Decreased activity local | phenotype |
| decreased neurite numbers local | phenotype |
| Decreased neurite numbers local | phenotype |
| Developmental induction local | phenotype |
| Development general local | phenotype |
| dibutyryl-cyclic AMP local | drug |
| disruption of early brain development local | phenotype |
| dominant_negative_nFGFR1_SP_NLS_TK local | variant |
| doublecortin local | phenotype |
| doublecortin+ neuroblasts local | phenotype |
| Early brain development local | anatomy |
| Early brain development disruption local | phenotype |
| early pioneer neuroblasts local | phenotype |
| Egfr | gene |
| Embryoid bodies local | drug |
| extracellular matrix local | phenotype |
| Extracellular matrix, proteases local | phenotype |
| Eye development local | phenotype |
| FGF2 | drug |
| FGFR1 | gene |
| FGFR1(SP-/NLS) local | variant |
| FGFR1(SP-/NLS(TK-)) local | variant |
| FGFR1(SP-/NLS)(TK-) local | variant |
| FGFR1(SP-/NLS)(TK-) transfected NCCs local | cohort |
| FGFR2 | gene |
| FGFR3 local | gene |
| FGFR4 | gene |
| First trimester local | anatomy |
| forebrain development local | phenotype |
| Forebrain development local | phenotype |
| forebrain-like region local | anatomy |
| Forming cortex local | anatomy |
| GABA receptor signaling local | phenotype |
| gastrulation local | phenotype |
| GDNF | drug |
| gene expression | phenotype |
| Germinal centers (rosettes) local | anatomy |
| GFAP | gene |
| GH | drug |
| glial development local | phenotype |
| Glial development local | phenotype |
| glutamate | drug |
| GSE103307 local | cohort |
| H9 local | cohort |
| H9 cerebral organoid local | cohort |
| H9_hESCs local | cohort |
| H9 line local | cohort |
| H9 (WA09) local | cohort |
| hESC H9 local | cohort |
| hESC H9 organoids local | cohort |
| hESC organoids local | cohort |
| hESCs | cohort |
| hESCs local | drug |
| hindbrain-like structure local | anatomy |
| hippocampal CA2 neuron local | anatomy |
| HUES8 local | cohort |
| HUES8 line local | cohort |
| human embryonic stem cells | cohort |
| hypoplasia | phenotype |
| IL-6 | drug |
| IL-8 local | drug |
| immature neurons | phenotype |
| Immature neurons local | anatomy |
| impaired cortical development local | phenotype |
| Impaired cortical development local | phenotype |
| impaired migration local | phenotype |
| Impaired migration local | phenotype |
| Impaired neuronal differentiation local | phenotype |
| INFS local | drug |
| Integrative Nuclear FGFR1 Signaling local | drug |
| intermediate zone | anatomy |
| Intermediate zone (IZ) local | anatomy |
| Intermediate Zone (IZ) local | anatomy |
| internal rosettes local | phenotype |
| interneuron | phenotype |
| iPSC_derived_NPCs local | cohort |
| iPSC line local | cohort |
| iPSC line 1835 local | cohort |
| iPSC line 2038 local | cohort |
| iPSC line 2937 local | cohort |
| iPSC line 3651 local | cohort |
| iPSC line BJ1 local | cohort |
| iPSC lines | cohort |
| iPSC organoid local | cohort |
| iPSC organoids local | cohort |
| iPSCs | cohort |
| Ki67 | drug |
| Ki67 local | phenotype |
| Ki67+ NPCs local | phenotype |
| Ki67+ proliferating cells local | anatomy |
| large neurons local | phenotype |
| learning and memory | phenotype |
| Limb, organ morphogenesis local | phenotype |
| Line 2038 local | cohort |
| Line 2937 local | cohort |
| LPS | drug |
| LTD | phenotype |
| LTP | phenotype |
| marginal CZ local | anatomy |
| Marginal Layer local | anatomy |
| matrigel | drug |
| melatonin | drug |
| microcephaly | phenotype |
| Microcephaly patients local | cohort |
| midbrain dopamine neuron local | anatomy |
| minor physical anomalies local | phenotype |
| MKI67 | gene |
| morphogens local | drug |
| mouse brain stem local | anatomy |
| Multicellular organism development local | phenotype |
| muscle development local | phenotype |
| MZ | anatomy |
| NCC local | cohort |
| NCC genes local | cohort |
| NCCs local | anatomy |
| NCCs local | cohort |
| NCCs local | phenotype |
| negative symptoms | phenotype |
| neocortex | anatomy |
| nervous system development | phenotype |
| neuroblasts | anatomy |
| Neuroectoderm local | drug |
| neurogenesis | phenotype |
| neuronal and brain development local | phenotype |
| neuronal differentiation | phenotype |
| neuronal NPC development local | phenotype |
| Neuronal programming local | phenotype |
| Neuronal projection local | phenotype |
| neurons | phenotype |
| newborn cells local | phenotype |
| nFGFR1 local | drug |
| nFGFR1 local | variant |
| nFGFR1-regulated genes local | gene |
| nFGFR1(SP-/NLS) local | variant |
| NGF | drug |
| Notch | gene |
| Notch1 local | gene |
| NPC | drug |
| NPC dispersion local | phenotype |
| NPCs local | anatomy |
| NPCs | cohort |
| NS/CNS development local | phenotype |
| Nur77 local | gene |
| Oligodendrocyte development local | phenotype |
| Organ and developmental morphogenesis local | phenotype |
| organoids | cohort |
| organoids local | phenotype |
| Outer cortical zone local | anatomy |
| Outer Cortical Zone local | anatomy |
| Pan-Neu local | drug |
| Pan-Neu local | phenotype |
| patients | cohort |
| PD173074 local | drug |
| PD173074-treated organoids local | cohort |
| PDGF | drug |
| pioneer neurons local | phenotype |
| pluripotency | phenotype |
| Pluripotent stem cells local | drug |
| polarity defects local | phenotype |
| Polarity defects local | phenotype |
| positive symptoms | phenotype |
| prefrontal cortex | anatomy |
| proliferating cells local | phenotype |
| Proliferating NPCs local | phenotype |
| radial glia local | phenotype |
| Radial glia local | phenotype |
| RARA | gene |
| reduced synaptic maturation local | phenotype |
| Reduced synaptic maturation local | phenotype |
| Regulation of signal transduction local | phenotype |
| Reln | gene |
| Response to retinoic acid local | phenotype |
| Rest | gene |
| retinoic acid | drug |
| RNAseq | drug |
| Rosette local | anatomy |
| Rosettes local | anatomy |
| RXR | gene |
| schizophrenia | phenotype |
| schizophrenia cohort local | cohort |
| Schizophrenia iPSC local | cohort |
| Schizophrenia iPSC lines local | cohort |
| schizophrenia iPSC organoids local | cohort |
| Schizophrenia iPSC organoids local | cohort |
| schizophrenia organoids local | phenotype |
| SCZ15 local | cohort |
| SCZ27 local | cohort |
| SCZ6 local | cohort |
| Sensory and motor cortical regions local | anatomy |
| study cohort | cohort |
| stunted cortical development local | phenotype |
| subcortical cells local | anatomy |
| Subcortical Circuits local | anatomy |
| subcortical neuronogenesis local | phenotype |
| subcortical regions | anatomy |
| subplate local | anatomy |
| sub-VZ local | anatomy |
| Synapse development, assembly local | phenotype |
| synapse formation | phenotype |
| synaptic plasticity | phenotype |
| Tbr1 | gene |
| telencephalon | anatomy |
| TGFβ | drug |
| Three patients local | cohort |
| TP53 | gene |
| transcription factors | drug |
| Transcription RNA PolII local | phenotype |
| Transcription RNA PolIII local | phenotype |
| TUBB3 | gene |
| Tuxedo pipeline local | drug |
| UPPER CORTICAL ZONE local | anatomy |
| ventricular zone | anatomy |
| Ventricular zone (VZ) local | anatomy |
| VZ | anatomy |
| white matter | anatomy |
| WNT | gene |
| β-galactosidase local | drug |
| βIII-tubulin local | phenotype |
No uploaded files.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Genetics of Alcohol Use Disorder: A Role for Induced Pluripotent Stem Cells? | 2018 | 29897633 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Investigating neural impairments in psychotic disorders using electroencephalography and cortical spheroids. | Reis de Assis D et al. | — | 2026 | → |
| Janus kinase/signal transducer and activator of transcription pathway in schizophrenia (Review). | Rizos E et al. | — | 2026 | → |
| Acid sphingomyelinase activity suggests a new antipsychotic pharmaco-treatment strategy for schizophrenia. | Chestnykh D et al. | — | 2025 | → |
| Biological age prediction in schizophrenia using brain MRI, gut microbiome and blood data. | Han R et al. | — | 2025 | → |
| Direct and Indirect Downstream Pathways That Regulate Repulsive Guidance Effects of FGF3 on Developing Thalamocortical Axons. | Li K et al. | — | 2025 | → |
| Integrating rare variant genetics and brain transcriptome data implicates novel schizophrenia putative risk genes. | Han S et al. | — | 2025 | → |
| Lower density of calretinin-immunopositive neurons in the putamen of subjects with schizophrenia. | Kelmer P et al. | — | 2025 | → |
| Modeling neurodegenerative diseases with brain organoids: from development to disease applications. | Larriba-González T et al. | — | 2025 | → |
| Modelling human brain development and disease with organoids. | Birtele M et al. | — | 2025 | → |
| Model systems for emulating human tissue and physiology in psychiatric research. | Cheng K et al. | — | 2025 | → |
| Neural Responses to Hypoxic Injury in a Vascularized Cerebral Organoid Model. | Li Y et al. | — | 2025 | → |
| Neurobiological Perturbations in Bipolar Disorder Compared With Schizophrenia: Evidence From Cell Cultures and Brain Organoids. | Akkouh IA et al. | — | 2025 | → |
| Repurposing medications to prevent psychosis. | Cohen BM et al. | — | 2025 | → |
| SELENOPROTEIN T deficiency alters projection neuron migration during corticogenesis in mice. | Carpentier E et al. | — | 2025 | → |
| α7 nicotinic acetylcholine receptors regulate radial glia fate in the developing human cortex. | Mukhtar T et al. | — | 2025 | → |
| Altered neuroepithelial morphogenesis and migration defects in iPSC-derived cerebral organoids and 2D neural stem cells in familial bipolar disorder. | Phalnikar K et al. | — | 2024 | → |
| Between neurons and networks: investigating mesoscale brain connectivity in neurological and psychiatric disorders. | Caznok Silveira AC et al. | — | 2024 | → |
| Current status and new avenues of stem cell-based preclinical and therapeutic approaches in amyotrophic lateral sclerosis. | Mazzini L et al. | — | 2024 | → |
| Dual-Hit Strategy for Therapeutic Targeting of Pancreatic Cancer in Patient-Derived Xenograft Tumors. | Roy Chaudhuri T et al. | — | 2024 | → |
| Genetics of human brain development. | Zhou Y et al. | — | 2024 | → |
| Harnessing stem cell-based approaches for clinically meaningful discoveries in schizophrenia. | Lizano P et al. | — | 2024 | → |
| Human stem cell-based models to study synaptic dysfunction and cognition in schizophrenia: A narrative review. | Santarriaga S et al. | — | 2024 | → |
| Identifying an Early Neuropathological Mechanism in Schizophrenia With Brain Organoids. | Kim J et al. | — | 2024 | → |
| Meta-analysis of single-cell RNA sequencing co-expression in human neural organoids reveals their high variability in recapitulating primary tissue. | Werner JM et al. | — | 2024 | → |
| Morphogenetic Designs, and Disease Models in Central Nervous System Organoids. | Bock M et al. | — | 2024 | → |
| Multiscale engineering of brain organoids for disease modeling. | Xu C et al. | — | 2024 | → |
| Patient-derived induced pluripotent stem cells: Tools to advance the understanding and drug discovery in Major Depressive Disorder. | Vaz A et al. | — | 2024 | → |
| Schizophrenia endothelial cells exhibit higher permeability and altered angiogenesis patterns in patient-derived organoids. | Stankovic I et al. | — | 2024 | → |
| Schizophrenia genomics: genetic complexity and functional insights. | Sullivan PF et al. | — | 2024 | → |
| Systems Genome: Coordinated Gene Activity Networks, Recurring Coordination Modules, and Genome Homeostasis in Developing Neurons. | Dhiman S et al. | — | 2024 | → |
| A beginner's guide on the use of brain organoids for neuroscientists: a systematic review. | Mulder LA et al. | — | 2023 | → |
| Advances in the knowledge and therapeutics of schizophrenia, major depression disorder, and bipolar disorder from human brain organoid research. | Villanueva R | — | 2023 | → |
| Advancing preclinical models of psychiatric disorders with human brain organoid cultures. | Dixon TA et al. | — | 2023 | → |
| Comparison of Oncogenes, Tumor Suppressors, and MicroRNAs Between Schizophrenia and Glioma: The Balance of Power. | Brown JS | — | 2023 | → |
| Disease-specific differences in gene expression, mitochondrial function and mitochondria-endoplasmic reticulum interactions in iPSC-derived cerebral organoids and cortical neurons in schizophrenia and bipolar disorder. | Kathuria A et al. | — | 2023 | → |
| Functional genomics in stem cell models: considerations and applications. | Shevade K et al. | — | 2023 | → |
| Schizophrenia-associated NRXN1 deletions induce developmental-timing- and cell-type-specific vulnerabilities in human brain organoids. | Sebastian R et al. | — | 2023 | → |
| Use of <i>in vitro</i> derived human neuronal models to study host-parasite interactions of <i>Toxoplasma gondii</i> in neurons and neuropathogenesis of chronic toxoplasmosis. | Halonen SK | — | 2023 | → |
| A Comprehensive Update of Cerebral Organoids between Applications and Challenges. | Li X et al. | — | 2022 | → |
| Advances in construction and modeling of functional neural circuits in vitro. | Chow SYA et al. | — | 2022 | → |
| [Cellular and supracellular models in the study of molecular mechanisms associated with schizophrenia]. | Karpov DS et al. | — | 2022 | → |
| Cerebral Organoids and Antisense Oligonucleotide Therapeutics: Challenges and Opportunities. | Lange J et al. | — | 2022 | → |
| Clozapine Reverses Dysfunction of Glutamatergic Neurons Derived From Clozapine-Responsive Schizophrenia Patients. | Hribkova H et al. | — | 2022 | → |
| Current advancements of modelling schizophrenia using patient-derived induced pluripotent stem cells. | Dubonyte U et al. | — | 2022 | → |
| Human Brain Organoid: A Versatile Tool for Modeling Neurodegeneration Diseases and for Drug Screening. | Ma C et al. | — | 2022 | → |
| Human-Induced Pluripotent Stem Cell Technology: Toward the Future of Personalized Psychiatry. | Alciati A et al. | — | 2022 | → |
| Modeling Developmental Brain Diseases Using Human Pluripotent Stem Cells-Derived Brain Organoids - Progress and Perspective. | Bhattacharya A et al. | — | 2022 | → |
| Modeling Schizophrenia In Vitro: Challenges and Insights on Studying Brain Cells. | Brandão-Teles C et al. | — | 2022 | → |
| Neurotoxicity of phenylalanine on human iPSC-derived cerebral organoids. | Kim J et al. | — | 2022 | → |
| Organotypic and Microphysiological Human Tissue Models for Drug Discovery and Development-Current State-of-the-Art and Future Perspectives. | Youhanna S et al. | — | 2022 | → |
| Patient-Derived In Vitro Models of Microglial Function and Synaptic Engulfment in Schizophrenia. | Sheridan SD et al. | — | 2022 | → |
| Reaching into the toolbox: Stem cell models to study neuropsychiatric disorders. | Whiteley JT et al. | — | 2022 | → |
| Regenerative Neurology and Regenerative Cardiology: Shared Hurdles and Achievements. | Mitrečić D et al. | — | 2022 | → |
| Region Specific Brain Organoids to Study Neurodevelopmental Disorders. | Susaimanickam PJ et al. | — | 2022 | → |
| Schizophrenia-associated<i>NRXN1</i>deletions induce developmental-timing- and cell-type-specific vulnerabilities in human brain organoids | Sebastian R et al. | — | 2022 | — |
| Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy. | Nicholson MW et al. | — | 2022 | → |
| What Makes Organoids Good Models of Human Neurogenesis? | Yang Q et al. | — | 2022 | → |
| 3D Bioprinting of Neural Tissues. | Cadena M et al. | — | 2021 | → |
| Advances in Central Nervous System Organoids: A Focus on Organoid-Based Models for Motor Neuron Disease. | Vieira de Sá R et al. | — | 2021 | → |
| Advancing Drug Discovery for Neurological Disorders Using iPSC-Derived Neural Organoids. | Costamagna G et al. | — | 2021 | → |
| A genome-wide association study identifies a gene network associated with paranoid schizophrenia and antipsychotics-induced tardive dyskinesia. | Levchenko A et al. | — | 2021 | → |
| Aiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications. | Lucido MJ et al. | — | 2021 | → |
| A protein-centric view of in vitro biological model systems for schizophrenia. | Chandrasekaran A et al. | — | 2021 | → |
| Brain organoid formation on decellularized porcine brain ECM hydrogels. | Simsa R et al. | — | 2021 | → |
| Brain Organoids: Filling the Need for a Human Model of Neurological Disorder. | Jalink P et al. | — | 2021 | → |
| Brain Organoids: Tiny Mirrors of Human Neurodevelopment and Neurological Disorders. | Yadav A et al. | — | 2021 | → |
| Building the brain from scratch: Engineering region-specific brain organoids from human stem cells to study neural development and disease. | Jacob F et al. | — | 2021 | → |
| Cellular Models in Schizophrenia Research. | Abashkin DA et al. | — | 2021 | → |
| Creation and use of organoids in biomedical research and healthcare: the bioethical and metabioethical issues. | Stoeklé HC et al. | — | 2021 | → |
| Directional Persistence of Cell Migration in Schizophrenia Patient-Derived Olfactory Cells. | Tee JY et al. | — | 2021 | → |
| From Brain Organoids to Networking Assembloids: Implications for Neuroendocrinology and Stress Medicine. | Makrygianni EA et al. | — | 2021 | → |
| Hippocampal regenerative medicine: neurogenic implications for addiction and mental disorders. | Peyton L et al. | — | 2021 | → |
| Human iPSC-Derived Glia as a Tool for Neuropsychiatric Research and Drug Development. | Heider J et al. | — | 2021 | → |
| Induced pluripotent stem cells for 2D and 3D modelling the biological basis of schizophrenia and screening possible therapeutics. | Tomaskovic-Crook E et al. | — | 2021 | → |
| Induced Pluripotent Stem Cells in Psychiatry: An Overview and Critical Perspective. | De Los Angeles A et al. | — | 2021 | → |
| Making Sense of Patient-Derived iPSCs, Transdifferentiated Neurons, Olfactory Neuronal Cells, and Cerebral Organoids as Models for Psychiatric Disorders. | Unterholzner J et al. | — | 2021 | → |
| Modeling neurological disorders using brain organoids. | Zhang DY et al. | — | 2021 | → |
| Modeling of Hypoxic Brain Injury through 3D Human Neural Organoids. | Kim MS et al. | — | 2021 | → |
| Modeling SARS-CoV-2 infection in individuals with opioid use disorder with brain organoids. | Willner MJ et al. | — | 2021 | → |
| Modeling Schizophrenia with Glioblastoma Cells: In Vitro Analysis of Risperidone Treatment on Glial Spheroids. | Somuncu OS et al. | — | 2021 | → |
| Modeling Somatic Mutations Associated With Neurodevelopmental Disorders in Human Brain Organoids. | Deb BK et al. | — | 2021 | → |
| Neurodevelopmental signatures of narcotic and neuropsychiatric risk factors in 3D human-derived forebrain organoids. | Notaras M et al. | — | 2021 | → |
| Novel Scalable and Simplified System to Generate Microglia-Containing Cerebral Organoids From Human Induced Pluripotent Stem Cells. | Bodnar B et al. | — | 2021 | → |
| Population-scale single-cell RNA-seq profiling across dopaminergic neuron differentiation. | Jerber J et al. | — | 2021 | → |
| Recent Trends and Perspectives in Cerebral Organoids Imaging and Analysis. | Brémond Martin C et al. | — | 2021 | → |
| The Perspectives of Early Diagnosis of Schizophrenia Through the Detection of Epigenomics-Based Biomarkers in iPSC-Derived Neurons. | Lee D et al. | — | 2021 | → |
| The proteomic architecture of schizophrenia iPSC-derived cerebral organoids reveals alterations in GWAS and neuronal development factors. | Notaras M et al. | — | 2021 | → |
| Transcriptomic Response under Heat Stress in Chickens Revealed the Regulation of Genes and Alteration of Metabolism to Maintain Homeostasis. | Kim H et al. | — | 2021 | → |
| A proof of concept 'phase zero' study of neurodevelopment using brain organoid models with Vis/near-infrared spectroscopy and electrophysiology. | Dutta A et al. | — | 2020 | → |
| Bioenergy Crisis in Coronavirus Diseases? | Dutta A et al. | — | 2020 | → |
| CNS organoids: an innovative tool for neurological disease modeling and drug neurotoxicity screening. | Chhibber T et al. | — | 2020 | → |
| Evidence for Decreased Density of Calretinin-Immunopositive Neurons in the Caudate Nucleus in Patients With Schizophrenia. | Adorjan I et al. | — | 2020 | → |
| Global Genome Conformational Programming during Neuronal Development Is Associated with CTCF and Nuclear FGFR1-The Genome Archipelago Model. | Decker B et al. | — | 2020 | → |
| Immune Factor, TNFα, Disrupts Human Brain Organoid Development Similar to Schizophrenia-Schizophrenia Increases Developmental Vulnerability to TNFα. | Benson CA et al. | — | 2020 | → |
| Innovations in 3-Dimensional Tissue Models of Human Brain Physiology and Diseases. | Lovett ML et al. | — | 2020 | → |
| Mitochondria under the spotlight: On the implications of mitochondrial dysfunction and its connectivity to neuropsychiatric disorders. | Zilocchi M et al. | — | 2020 | → |
| Modeling alcohol-induced neurotoxicity using human induced pluripotent stem cell-derived three-dimensional cerebral organoids. | Arzua T et al. | — | 2020 | → |
| Modeling Psychiatric Disorder Biology with Stem Cells. | Das D et al. | — | 2020 | → |
| Stem Cells for Improving the Treatment of Neurodevelopmental Disorders. | Donegan JJ et al. | — | 2020 | → |
| The abiding relevance of mouse models of rare mutations to psychiatric neuroscience and therapeutics. | Gogos JA et al. | — | 2020 | → |
| The Application of Brain Organoids: From Neuronal Development to Neurological Diseases. | Shou Y et al. | — | 2020 | → |
| Three-dimensional modeling of human neurodegeneration: brain organoids coming of age. | Grenier K et al. | — | 2020 | → |
| Transcriptomic Landscape and Functional Characterization of Induced Pluripotent Stem Cell-Derived Cerebral Organoids in Schizophrenia. | Kathuria A et al. | — | 2020 | → |
| Analysis of Light Propagation on Physiological Properties of Neurons for Nanoscale Optogenetics. | Wirdatmadja S et al. | — | 2019 | → |
| A Simple Procedure for Creating Scalable Phenotypic Screening Assays in Human Neurons. | Sridharan B et al. | — | 2019 | → |
| Brain organoids and insights on human evolution. | Muotri AR | — | 2019 | → |
| Compartmentalized Devices as Tools for Investigation of Human Brain Network Dynamics. | Fantuzzo JA et al. | — | 2019 | → |
| Contribution of induced pluripotent stem cell technologies to the understanding of cellular phenotypes in schizophrenia. | Balan S et al. | — | 2019 | → |
| iPSCs-Based Neural 3D Systems: A Multidimensional Approach for Disease Modeling and Drug Discovery. | Costamagna G et al. | — | 2019 | → |
| Modelling Protein Synthesis as A Biomarker in Fragile X Syndrome Patient-Derived Cells. | Pal R et al. | — | 2019 | → |
| Moral Limits of Brain Organoid Research. | Koplin JJ et al. | — | 2019 | → |
| Neural Lineage Differentiation From Pluripotent Stem Cells to Mimic Human Brain Tissues. | Hong YJ et al. | — | 2019 | → |
| Optogenetics in the Era of Cerebral Organoids. | Shiri Z et al. | — | 2019 | → |
| Primary Cilia-An Underexplored Topic in Major Mental Illness. | Pruski M et al. | — | 2019 | → |
| Progress in iPSC-Based Modeling of Psychiatric Disorders. | Hoffmann A et al. | — | 2019 | → |
| Studying Heterotypic Cell⁻Cell Interactions in the Human Brain Using Pluripotent Stem Cell Models for Neurodegeneration. | Song L et al. | — | 2019 | → |
| Use of human pluripotent stem cell-derived cells for neurodegenerative disease modeling and drug screening platform. | Garcia-Leon JA et al. | — | 2019 | → |
| Brain Organoids: Expanding Our Understanding of Human Development and Disease. | Chuye LB et al. | — | 2018 | → |
| Genetics of Alcohol Use Disorder: A Role for Induced Pluripotent Stem Cells? | Prytkova I et al. | — | 2018 | → |
| Induced Pluripotent Stem Cells Reveal Common Neurodevelopmental Genome Deprograming in Schizophrenia. | Narla ST et al. | — | 2018 | → |
| Stem Cells, Genome Editing, and the Path to Translational Medicine. | Soldner F et al. | — | 2018 | → |
| The <i>DGCR5</i> long noncoding RNA may regulate expression of several schizophrenia-related genes. | Meng Q et al. | — | 2018 | → |